CLBS16

BIOLOGICAL2 trials

Sponsors

Lisata Therapeutics, Inc.

Conditions

Coronary Microvascular DiseaseCoronary Microvascular DysfunctionMicrovascular Coronary Artery Disease

Phase 2

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

CompletedNCT03508609

Lisata Therapeutics, Inc.Coronary Microvascular Dysfunction

Start: 2018-04-19End: 2020-05-05Updated: 2021-01-08

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

TerminatedNCT04614467

Lisata Therapeutics, Inc.Coronary Microvascular Disease, Coronary Microvascular Dysfunction, Microvascular Coronary Artery Disease

Start: 2020-10-29End: 2022-09-28Updated: 2026-05-04

Related Papers

Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction

Circulation Cardiovascular Interventions2022-01-2448 citations

Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair-A Systematic Review.

2021-05-0819 citations